Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

7(87.5%)

Phase 2

1(12.5%)

8Total

N/A(7)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06968299Not ApplicableRecruiting

Effect of ExoBDNF Lactic Acid Bacteria Supplement on Cognitive Functions, Sleep and Psychological

Role: lead

NCT05737342Not ApplicableRecruiting

Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose

Role: lead

NCT05737355Not ApplicableRecruiting

Effect of ANKASCIN 568-P Products Regulating Blood Lipid

Role: lead

NCT05869799Not ApplicableUnknown

Effect of Vigiis 101 Lactic Acid Bacteria Powder on Body Weight and Body Fat in Overweight Participants

Role: lead

NCT05719649Not ApplicableUnknown

The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis Clinical Trial

Role: lead

NCT05664139Phase 2Unknown

Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma

Role: collaborator

NCT04088474Not ApplicableCompleted

Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora

Role: lead

NCT04046432Not ApplicableCompleted

Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora, Peristalsis, Immunity, and Anti-oxidative Capacity

Role: lead

All 8 trials loaded